Needham & Company Downgrades NuVasive (NUVA) to Hold

Needham & Company downgraded NuVasive (NASDAQ: NUVA) from Buy to Hold saying growth is likely to slow.

Analyst Mike Matson comments, "We are downgrading NUVA to Hold from Buy since we expect revenue growth to slow, limiting multiple expansion and making operating margin expansion more difficult. While 2014 guidance appears conservative, we worry that 2015 revenue growth expectations are too high. Additionally, NUVA's OIG subpoena remains an overhang and we see a greater probability of a settlement in the next 12 months than we had seen in the prior 12 months. We now view NUVA shares as fairly valued."

For an analyst ratings summary and ratings history on NuVasive click here. For more ratings news on NuVasive click here.

Shares of NuVasive closed at $33.11 yesterday.

You May Also Be Interested In

• Needham Starts Faeth Therapeutics (FTH) at Buy
• Viking Holdings (VIK) PT Raised to $82 at Mizuho
• Deere (DE) PT Raised to $585 at JPMorgan